NCT03062423View on ClinicalTrials.gov

A Bio-equivalence Study of Sofosbuvir From Sofodelevier 400 mg Film Coated Tablets (Al-debeiky Pharma, Egypt) Versus Sovaldi 400 mg Tablets (Gilead Sciences, Canada)

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

October 31, 2016

Study Completion Date

November 30, 2016

Conditions
Healthy
Interventions
DRUG

Sofodelevier

1 tablet contains 400 mg sofosbuvir

DRUG

Sovaldi (fist dose)

1 tablet contains 400 mg sofosbuvir

DRUG

Sovaldi (second dose)

1 tablet contains 400 mg sofosbuvir

Trial Locations (1)

11757

Genuine Research Center GRC, Cairo

Sponsors

Collaborators (1)

Al-debeiky pharma
All Listed Sponsors
collaborator

Al-debeiky pharma

UNKNOWN

lead

Genuine Research Center, Egypt

INDUSTRY

NCT03062423 - A Bio-equivalence Study of Sofosbuvir From Sofodelevier 400 mg Film Coated Tablets (Al-debeiky Pharma, Egypt) Versus Sovaldi 400 mg Tablets (Gilead Sciences, Canada) | Biotech Hunter | Biotech Hunter